Detail akcie BioXcel Therptc Rg online

Business Summary: BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, BioXcel Therapeutics Inc revenues increased 89% to $1.9M. Net loss decreased 69% to $48.7M. Revenues reflect PHARMACEUTICAL PREPARATIONS segment increase from $798K to $1.9M. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 44% to $56.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$86.46 to -$22.34.